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Available online 1 July 2016Nonacog beta pegol (N9-GP) is a novel recombinant factor IX conjugated with a 40-kDa branched polyethylene
glycol (PEG) to extend plasma half-life (t½) compared with native FIX, developed for the treatment of
haemophilia B.
This is the ﬁrst time distribution, metabolism, and excretion data of N9-GP have been presented. ADME studies
were performed using single i.v. doses of radiolabelled N9-GP administered to rats, focussing on the biological
fate of the 40-kDa PEG. Results indicated that N9-GP-related radioactivity was distributed throughout the
body, beingmost abundant in highly vascularised tissues, and with lowest levels seen in the central nervous sys-
tem. N9-GP was cleared from plasma within 1 week after dosing, while total radioactivity was eliminated more
slowly, in amore pronounced biphasicmanner. N9-GP seems to be cleared via receptor-mediated uptake (e.g., in
the liver) or via the reticuloendothelial system with subsequent proteolysis. PEG is thereafter either cleared
alongside the protein or released back into circulation. Furthermore, N9-GP-related radioactivity was excreted
in both faeces andurine as 40 kDa PEG and degradation products. SomePEG-related radioactivity (not in any par-
ticular organ) was present in the carcass 12 weeks postdose, consistent with the long terminal elimination t½ of
plasma radioactivity.
As shown here for N9-GP, and previously for other protein-PEG conjugate products, disposition kinetics of con-
jugates and individual constituents appears to be compound speciﬁc. In addition to the size/structure of the PEG
and protein moieties, protein-speciﬁc clearance pathways may contribute to the disposition of intact conjugate
and PEG moiety.
© 2016 Novo Nordisk. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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.V. This is an open access article unde(Srivastava et al., 2013). The gold-standard treatment for haemophilia
B is based on replacement of the missing clotting factor using regular
and continued intravenous (i.v.) injections of FIX concentrates (prophy-
laxis) (Srivastava et al., 2013). Standard FIX concentrates have a half-life
of 17–23 h (Björkman et al., 2001; Lambert et al., 2007; White et al.,
1998), with effective prophylaxis typically requiring 40–100 IU/kg in-
jections, 1–2 times per week (Valentino et al., 2014).
To reduce the dosing frequency of therapeutic proteins, one
established technique that has been successfully used is half-life (t½)
extension by way of conjugation with water-soluble polymers such as
polyethylene glycol (PEG) (Carr and Tortella, 2015; Ivens et al., 2013;
Kang et al., 2009; Metzner et al., 2009). The prolonged circulation time
resulting from PEGylation is thought to be due to increased retention
of the protein in the circulation via protection against receptor-mediat-
ed uptake and enzymatic catabolism, reduced renal excretion, and re-
duced levels of neutralising antibodies due to PEG-related steric
hindrance (Cai et al., 2012; Hamidi et al., 2006).
Nonacog beta pegol (also called N9-GP) is a novel PEGylated recom-
binant FIX (rFIX) conjugate with an extended half-life compared with
native FIX. N9-GP consists of a high molecular weight (MW) (40 kDa)
branched PEG moiety that is covalently attached to one of the nativer the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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glycoPEGylation (Collins et al., 2012; Ostergaard et al., 2011). A
branched PEG moiety was selected as these tend to have longer half-
lives than linear PEGs (Production of PEGylated Proteins, 2012). Con-
trolled glycoPEGylation was used to avoid the increased risk of protein
immunogenicity reported for random PEGylation and conjugation
with a single large PEG, as opposed to multiple small PEGs, was
employed to ensure preservation of the catalytic activity of the protein
(Production of PEGylated Proteins, 2012).
During coagulation, the activation peptide is cleaved from N9-GP
along with the PEG moiety, releasing activated FIX (FIXa) protein
(Collins et al., 2012; Ostergaard et al., 2011). Compared with standard
rFIX therapies, N9-GP is associated with a markedly prolonged t½ in an-
imals (up to 76 h in mini-pigs and 113 h in haemophilia B dogs vs. 16
and 25 h, respectively, for rFIX) (Ostergaard et al., 2011) and a 5-fold in-
crease in t½ in humans (up to ~110 hwith the 40-IU/kg dose) (Collins et
al., 2014; Negrier et al., 2011; Ostergaard et al., 2011). These data sug-
gest that N9-GP may enable effective prophylaxis with less frequent in-
fusions than standard rFIX therapies (Collins et al., 2012; Collins et al.,
2014; Mancuso, 2014).
Long-term animal studies of N9-GP (Offenberg et al., 2015b) and
other PEGylated therapeutic proteins have not raised any PEG-related
safety concerns at clinically relevant doses (Ivens et al., 2013; Ivens et
al., 2015; Offenberg et al., 2015a; Webster et al., 2007). In general,
healthy animals with normal coagulation have been used in these
types of studies as well as in absorption, distribution, metabolism, and
excretion (ADME) studies. Although this means that the animals
would be unlikely to utilise any of the dosed rFIX (N9-GP), the study
of healthy animals is still deemed relevant as even low therapeutic
doses provide a large excess of circulating rFIX (here asN9-GP). Further-
more, rFIX would only be activated during a bleeding episode, which
would be less likely in the controlled environment of such studies.
The aim of these investigations was to describe the biological fate
(plasma kinetics, tissue distribution, metabolism [including proﬁling],
and excretion) of N9-GP, with special focus on the 40-kDa PEG moiety.
Studies were performed using single i.v. bolus doses of radiolabelled
N9-GP administered to rats. Although the pharmacokinetics of several
protein-PEG conjugate products, as well as PEG of various molecular
weights, have been described previously (Yamaoka et al., 1994;
Caliceti and Veronese, 2003; Kang et al., 2009; Nesbitt et al., 2009; Cai
et al., 2012; Elliott et al., 2012; Woodburn et al., 2012; Ivens et al.,
2013; Bjørnsdottir et al., 2016; Stidl et al., 2016), the distribution and
elimination of the conjugate appears to be compound speciﬁc. Parame-
ters inﬂuencing the conjugate's ADME properties include the size and
structure of the PEG and the protein moieties as well as any speciﬁc
clearance mechanisms attributable to the protein part (e.g., receptor-
mediated uptake). The latter could also be expected to affect the dispo-
sition of the PEG moiety of the conjugate. Investigation of the ADME
properties of each PEGylated molecule is therefore relevant. This is the
ﬁrst time distribution, metabolism, and excretion data of N9-GP has
been presented.
2. Materials and methods
Radiolabelled and unlabelledN9-GP (averageMW including the PEG
moiety: ~98,000 Da) was produced by Novo Nordisk A/S, Måløv, Den-
mark. Doses administered in the described studies were based on the
full MW, not only that of the protein. For estimation of IU doses, 1 mg
protein was assumed to be equivalent to 150 IU. All other solvents and
reagents were of analytic grade and purchased from commercial
suppliers.
2.1. Synthesis of radiotracers
Two different radiolabelled versions of N9-GP were produced using
either a [3H]-label inserted in the PEG moiety ([3H]N9-GP) or a [14C]-label inserted in the linker region ([14C]N9-GP) (Fig. 1). The method
used to [3H]-label the PEG moiety has been previously described
(Bjørnsdottir et al., 2016). The radiochemical purity of [3H]N9-GP conju-
gate was 83% (75% mono-PEGylated and 8% di-PEGylated) and the spe-
ciﬁc activity was estimated to be 47 Ci/mmol.
[14C]N9-GP was synthesised in six steps starting from Fmoc-
[U-14C]Gly-OSu (supplied byQuotient Bioresearch, Cardiff, United King-
dom), using the procedure followed for synthesis of unlabelled N9-GP
(Ostergaard et al., 2011). The radiochemical purity of [14C]N9-GP was
N92% and the speciﬁc activity was estimated to be 0.138 Ci/mmol.
2.2. In vitro activity of [3H]N9-GP
The activity of the protein componentwas assessed using a commer-
cially available FIX chromogenic assay (Haemochrom Diagnostica
GmbH, Essen, Germany) for the [3H]N9-GP tracer.
2.3. Laboratory animals
All protocols for the in vivo studies were reviewed and approved by
the ethical review council at Novo Nordisk A/S prior to the start of the
studies. All rats used in the in vivo studies were obtained from UK
Home Ofﬁce-approved sources, and the studies were conducted at
Covance Laboratories (Harrogate, United Kingdom) under a UK Home
Ofﬁce license and laboratory procedures were fully commensurate
with international standards of good laboratory practice. Male Han
Wistar rats (HsdHan™, WIST) with an initial weight of between 268
and 381 g (N6 weeks old) were used in all studies. Rats used for the
[3H]N9-GP studies were obtained from Charles River UK Ltd. (Margate,
United Kingdom), while those for the excretion study with [14C]N9-GP
were obtained from Harlan (Blackthorn, United Kingdom). Rats were
housed and fed in accordance with the protocol described by
Bjørnsdottir et al. (2016).
The authors believe that the pharmacokinetic effect of using rats
from different vendors is limited since the rats were of the same strain
and of comparable weight and age.
2.4. Experimental methods
2.4.1. Tissue distribution ([3H]N9-GP, rats)
MaleHanWistar rats received a single i.v. bolus dose of [3H]N9-GP at
1.5 mg/kg (27 MBq/kg; ~127 IU/kg, 0.6 mg/kg PEG load). Immediately
prior to sacriﬁce, a blood samplewas collected from each animal by car-
diac puncture into tubes coated with sodium citrate. Plasma samples
were divided into two: one aliquot was analysed directly by liquid scin-
tillation counting (LSC), the other was freeze dried, reconstituted in
water, and analysed by LSC to derive the content of volatile tritiated
water (3H2O).
Quantitative whole-body autoradiography (QWBA) was performed
as previously described (n = 1 per time point) (Bjørnsdottir et al.,
2016). The sampling time points were 1, 12, 24, and 96 h, and 1, 2, 5,
9, and 12 weeks postdose. The tissue radioactivity was measured
using a validated image analysis system.
For the micro-autoradiography (MARG) phase, rats (n= 1 per time
point) were killed by isoﬂurane inhalation anaesthetic overdose follow-
ed by cervical dislocation at 1, 24, and 96 h postdose. Liver, kidney,
spleen, brain, testis, heart, adrenal, and bone marrow were collected
and samples were freeze-embedded in OCT (Optimal Cutting Tempera-
ture; Cellpath, Newtown, United Kingdom) reagent, placed in a Leica
CM3050 cryo-microtome (Leica Microsystems [UK] Ltd., United King-
dom), and replicated 5-μm sections cut. Sections were thaw-mounted
onto microscope slides precoated with nuclear photographic emulsion.
After autoradiographic exposure for 7, 21, or 35 days, the slides were
photographically processed, histologically stained, and microscopically
evaluated.
Fig. 1. Structure of radiolabelled 40 kDa PEGylated N9-GP and positions of the 3H and 14C labels.
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rat)
For excretion recovery and plasma samples, eachmaleWistar rat re-
ceived a single i.v. dose of either [3H]N9-GP (1.5 mg/kg body weight;
27 MBq/kg; ~ 127 IU/kg, PEG-load ~0.6 mg/kg) or [14C]-N9-GP
(0.3mg/kg; 0.15MBq/kg; ~25 IU/kg, PEG-load ~0.12mg/kg). For the ex-
cretion studies, rats (n= 3 per study) were placed in glass metabolism
cages suitable for the separate collection of urine and faeces on the af-
ternoon prior to dose administration. The rats were kept in the metab-
olism cages continuously for the ﬁrst 7 days of the study period
(collection intervals: 0–24 [day 1], 24–48 [day 2], 48–72 [day 3], 72–
96 [day 4], 96–120 [day 5], 120–144 [day 6], and 144–168 [day 7] h)
and thereafter for 24-h intervals on a weekly basis up to 12 weeks; on
days 14, 21, 28, 35, 42, 49, 56, 63, 70, 77, and 84 for the [3H]N9-GP anal-
ysis and a day later (days 15–85, respectively) for the [14C]PEG-N9-GP
analysis. In addition to urine and faeces, cage wash samples were also
collected.
Blood was collected from the jugular vein or tail vein in a total of 12
rats (n=6 × 2) for each compound; six rats were sampled at 5 min
1, 6, and 24 h and 1, 3, 5, 7, 9, and 11weeks postdose and the other 6
rats at 30min, 2, 8, and 48 h and 2, 4, 6, 8, 10, and 12weeks postdose.
Blood samples were pooled for each group of six animals per time
point for each compound. Blood samples from rats dosed with
[3H]N9-GP were split into two aliquots; the ﬁrst was transferred
into a tube containing sodium citrate and the second into to a tube
containing ethylenediamine tetra-acetic acid as anticoagulants. Plas-
mawas extracted from an aliquot of each by centrifuging at 2500×g
for 15 min (20 °C) and samples were analysed, in duplicate, for ra-
dioactivity using LSC. For rats dosed with [14C]N9-GP, pooled blood
samples were transferred into tubes containing sodium citrate and
plasma was extracted as before. One set of plasma samples from
each studywas analysed by luminescent oxygen-channelling immu-
noassay (LOCI) and the remainder was used for radioactivity proﬁl-
ing using LSC and/or accelerator mass spectrometry (AMS). Citrated
plasmawas used for the LOCI assay as per assay validation. The HPLC
proﬁles were conducted with EDTA plasma in one study ([3H]N9-
GP) and citrated plasma in the other study ([14C]N9-GP). In vitro in-
vestigation of the blood to plasma ratio showed similar results
(within 0.4–0.8) regardless of selected anticoagulant (EDTA, citrate,
or heparin; data not included in this paper). These data veriﬁed that
partitioning of [3H]N9-GP, [14C]N9-GP, and related radioactivity into
blood cells is negligible, and that plasma is a relevant matrix forassessing PK parameters and metabolism proﬁles regardless of se-
lected anticoagulant.
2.4.3. In vivo stability of the [3H]-tracer
The in vivo stability of the radioactive tracers in plasma was moni-
tored over time (up to 12 weeks postdose) as part of the QWBA study
using the generated amount of tritiated water as a quality marker.
This involved measuring the amount of total radioactivity before and
after freeze-drying plasma samples.
2.4.4. LOCI for the detection of N9-GP in rat plasma
A validated homogenous bead-based LOCI assay was used for the
quantiﬁcation of N9-GP in plasma samples. One of the bead reagents
was a generic reagent (D-beads) coated with streptavidin and contain-
ing a photosensitive dye. The second bead reagent (A-beads) was
coated with a monoclonal antibody directed against human FIX (hFIX)
tomake up the sandwich. The amount of chemiluminescence generated
when the complex was illuminated (measured in an EnVision® Plate
Reader; Perkin Elmer, Waltham, MA, USA) was proportional to the
concentration of hFIX. The lower limit of quantiﬁcation (LLOQ) was
15 ng/mL (0.3 nM).
As the LOCI assay was speciﬁc for hFIX, it would detect both the in-
tact N9-GP conjugate as well as any free FIX, but not the free PEGmoie-
ty. As (r)FIX will have a much faster turnover rate than N9-GP, the
contribution of any free FIX to total concentrations measured by the
LOCI is deemed to be low. Henceforth, only N9-GP will be referred to
when discussing the LOCI data.
2.5. PK analysis
Plasma radioactivity concentration versus time data from the excre-
tion balance were used to assess the distribution and elimination kinet-
ics of total plasma radioactivity stemming from single i.v. doses of
radiolabelled N9-GP. Plasma radioactivity concentration data from the
QWBA study were not used for any calculations due to the limited
early sampling frequency, but data was used for plotting. Radioactive
concentrations were transformed to nmol equivalents/g plasma using
the speciﬁc activity of the respective radioactive formulations (further
simpliﬁed to nmol/l assuming a matrix density of 1 g/mL). The plasma
kinetics of N9-GP conjugate after [3H]N9-GP i.v. dosing was assessed
using LOCI measurements. All PK analyses were performed using Phoe-
nix™WinNonlin® version 6.4 (Pharsight, St Louis, MI, USA).
As blood samples were collected using a sparse-sampling design,
mean composite plasma proﬁles were produced from pooled samples
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dose level prior to standard non-compartmental analysis (NCA). The
linear up/log down trapezoidal calculation method was used for NCA.
The PK parameters assessed by NCA were the back-extrapolated
concentration at time zero (C0), initial disposition half-life (t½α) and
t½ (based on linear regression of the log-linear initial and terminal
phases, respectively), mean residence time (MRT), total plasma clear-
ance (CL), volume of distribution at steady state (Vss), and the areas
under the plasma concentration–time curves from zero to time t
(AUC[0–t]), and from zero to inﬁnity (AUC). The extrapolated area
(AUCextrap) from the last sampling time point to inﬁnity was also
estimated.
In addition to NCA, the PK of N9-GP and N9-GP-related radioactivity
was evaluated using a standard open 2-compartmental i.v. bolus ﬁrst-
order eliminationmodel (Fig. 2). Estimated model parameters included
volumes of the central and peripheral distribution compartments (Vc
and Vp), the inter-compartment distribution clearance (CLd), and CL. A
proportional error model was used for ﬁtting the model to the plasma
concentration data. The Phoenix module used for modelling was the
‘NMLE7’with ‘population: naïve pooled’ engine selected, with ordinary
differential equations (ODE) solver method set to ‘matrix exponent’.
The model ﬁts to the data were evaluated visually (using various good-
ness-of-ﬁt plots) and statistically (using the Akaike information criteria
[AIC]).
2.6. Analytical methods
2.6.1. HPLC and radiochemical detection used for metabolite proﬁling of
[3H]N9-GP and [14C]N9-GP samples
High-performance liquid chromatography (HPLC) analysis was con-
ducted on a Dionex ultimate 3000 HPLC system (Thermo Scientiﬁc,
Waltham, MA, USA), equipped with a Phenomenex Jupiter C4 column
(5 μm, 300 Å, 4.6 × 250 mm). The mobile phases consisted of A:
TFA:2-propanol:acetonitrile:water 0.5:60:140:800 (v/v) and B: TFA:2-
propanol:acetonitrile 0.5:300:700 (v/v). The system was operated in
gradient mode (step gradient from 0 to 1 min: 0% B; 1–9 min: 0% B to
26% B; 9–10 min: 26% B to 30% B; 10–16 min: 30% B; 16–18 min: 30
to 41% B; 18–24 min: 41% B; 24–27 min: 41% to 80% B; 27–28 min:
80% to 0% B; 28–38 min: 0% B at 30 °C). HPLC eluent fractions from
the [3H]N9-GP samples were collected in 96-well Deepwell Lumaplates
(Perkin Elmer, Waltham, MA, USA) with a rate of 0.25 mL/well (collec-
tion time 15 s). Lumaplates were dried overnight and the amount of ra-
dioactivity present measured using a TopCount NXT scintillation
counter (Perkin Elmer). The Jupiter C4 column was selected for metab-
olite proﬁling as it provided sharp peaks for both [3H]PEG and [3H]N9-Fig. 2. The open two-compartmental i.v. bolus ﬁrst-order elimination model used to
describe the plasma disposition of N9-GP and total radioactivity. CLd, distribution
clearance; CL, total clearance; Vc and Vp, volume of distribution of the central and
peripheral compartments.GP, as well as an optimal elution order (40 kDa [3H]PEG eluting before
[3H]N9-GP). Smaller-sized PEGs (4–30 kDa) were found to elute be-
tween the front and the [3H]PEG; however, column carry over was ob-
served (~2% for both compounds) during method development so
precautions were taken. The samples were analysed in the order of in-
creasing amount of radioactivity and the HPLC system cleaned via injec-
tion of water between samples. Background radioactivity levels were
also evaluated between analyses of each matrix for analysis of the
[3H]N9-GP samples.
For the [3H]N9-GP samples, pooled plasma samples (5 min, 8 and
24 h, and 1, 2, and 4weeks, n=6/time point) were prepared bymixing
plasma andmethanol (2:1 v/v), incubating on ice for 5min, centrifuging
at ~13,800×g for 10 min at 5 °C, and evaporating the supernatant to
dryness under N2 and heat (40 °C). The pellet was reconstituted in
Milli-Q water prior to HPLC analysis. The preparation recovery was
79–115%, which was considered acceptable as the proﬁles were not
quantitatively evaluated. Urine samples (0–24 h, 24–48 h, and 48–
72 h, n = 3/time point) were pooled and injected directly on to the
HPLC without further preparation. Faeces samples were pooled (0–24,
24–48 h, and 48–72 h, n=3/time point) and homogenised, and a 1g al-
iquot was extracted ﬁve times with 1.0 mL of Milli-Q water at room
temperature. The mixture was centrifuged for 5 min at 2000×g at
15 °C. The aqueous phases were combined and evaporated under N2
and heat (40 °C) to approximately 1 mL. Prior to HPLC analysis, the ex-
tractswere centrifuged for 5min at approximately 2000×g at 15 °C. The
preparation recoverywas 18.5–22.5%,whichwas considered acceptable
in view of the difﬁculty in extracting PEG from this type of matrix, and
as the proﬁles were not quantitatively evaluated.
For the [14C]N9-GP samples, the same sample preparationmethod as
used for [3H]N9-GPwas utilised for the selected plasma samples (5min,
24 h, and 1, 2, 4, and 12weeks, n=6/time point) and the urine samples
(0–24 and 48–72 h, 1 week (day 7), 4 weeks (day 29), and 12 weeks
(day 85), whereas the preparation of the faeces sample (a pool faeces
homogenates from 3 rats, 0–168 h) was slightly modiﬁed by omitting
the ﬁnal evaporation step. HPLC eluent fractions from the [14C]N9-GP
samples were collected in 96-well racks with plastic latch track tubes
(Thermo Scientiﬁc, Waltham, MA, USA [collection time 20 s]) and
shipped on dry ice to Xceleron Inc. for further AMS analysis.
2.6.2. AMS analysis
The original plasma, urine, and faeces samples as well as the derived
HPLC fractions from [14C]N9-GP dosed ratswere analysed for total [14C]-
radioactivity using AMS (at Xceleron Inc., Germantown, MD, USA). The
AMS was a 250-kV Single Stage Accelerator Mass Spectrometer.
Brieﬂy, sample pretreatment consisted of the conversion of the car-
bon within the samples to graphite via a 2-step process of combustion
(oxidation) and graphitisation (reduction). Combustion was performed
under vacuum at 900 °C for 2 h in a heat-sealed tube by heating the
dried sample with copper oxide using a calibrated lab oven (Carbolite
CWF 12/23 furnace). Graphitisation was performed by heating the car-
bon dioxide formed from the oxidised sample with zinc, titanium hy-
dride, and cobalt at 500 °C for 4 h, followed by a further 6 h at 550 °C.
The graphite was pressed into a cathode in the AMS instrument and
bombarded with high-energy caesium (Cs+) ions. The resulting nega-
tive carbon ion beamwas introduced into the AMS instrument, acceler-
ated by an electric ﬁeld of 4.5 MV, and the carbon atoms were stripped
of their valency electrons. This resulted in separation of the carbon
isotopical elements as C4+ ions. The carbon isotopes 12C and 13C were
quantitated using Faraday cups, while 14C was quantitated by a silicon
surface barrier detector.
The total carbon content of sample and carrierwas determined using
a carbon, hydrogen, and nitrogen analyser (PerkinElmer 2400 Series II
CHN S/O analyser). The natural background [14C]/[12C] level per matrix
was then subtracted to obtain the amount of N9-GP-related 14C. The
total carbon content and the speciﬁc activity of [14C]N9-GP was used
to convert the [14C]/[12C] ratio to N9-GP equivalents (ng/mL sample or
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0.028 ng equivalents/mL. Further details related to the design of the
AMS instrument have previously been described (Lappin, 2006;
Lappin and Garner, 2004).2.6.3. Gel electrophoresis
Plasma and urine samples and [3H]-reference substances were elec-
trophoresed in low melting point agarose (4% in TBE buffer, pH 8.3) in
duplicate (at 150 V for 3 h). As matrix effects were observed during
method development, [3H]-reference substanceswere prepared in plas-
ma and urine, respectively, where after both samplematrices were con-
centrated and reconstituted in plasma.
The recommended minimum radioactive loading dose was deter-
mined to ~5000 dpm; no maximum dose was determined. Each gel
lane was divided into two sections, from the well towards the negative
pole (i.e., PEG section) and from the well towards the positive pole (i.e.,
N9-GP section). As negative controls, gel slices were obtained from
lanes that were not dosed with radioactive samples or references. The
gel slices were added to scintillation cocktail (Ultima Gold, Perkin
Elmer Life and Analytical Sciences, Boston, MA, USA), and heated at
70 °C for 15 min under gentle agitation, then analysed for their radioac-
tive amount by LSC (Tri-carb 2910TR liquid scintillation analyser, Perkin
Elmer Life and Analytical Sciences, Boston, MA, USA). The obtained data
were used to calculate the recovery and distribution of radioactivity
within the gel lanes. The limit of detection was deﬁned as 130 dpm.3. Results
3.1. In vitro activity of [3H]N9-GP
[3H]N9-GP showed 72.6 ± 2.4% activity compared to a N9-GP refer-
ence compound, indicating that the radiotracer had retained close to full
in vitro FIX activity.3.2. In vivo stability of the [3H] tracer
The [3H]-tracer were found to be stable as very little, or no,
radiolabelled water was detected in plasma samples throughout the
studies (up to 12 weeks postdose).Fig. 3. Tissue/organ distribution of radioactivity 1, 12, 24, and 96 h, and 1, 2, 5, 9, and 12weeks a
in male Wistar rats (n= 1 per time point) according to quantitative whole-body autoradiogra3.3. Tissue distribution of [3H]N9-GP
QWBA showed that [3H]PEG-related radioactivity was distributed
throughout the body of the rat, with the highest levels found in highly
vascularised tissues and the lowest levels in the central nervous sys-
tem (CNS: brain and spinal cord) (Fig. 3). The highest measurements
(N 5.0 μg eq. N9-GP/g to a maximum of 18.5 μg eq. N9-GP/g) at sam-
pling times up to 24 h postdose were generally associated with the uri-
nary bladder (contents), blood, plasma, bile ducts, liver, adrenal glands,
bulbo-urethral gland, and lungs. At later sampling times (48 h up to
9 weeks postdose), the highest levels of radioactivity were associated
with the lymph. The concentration in the brain was 0.276 μg eq. N9-
GP/g at 1 h postdose, declining to 0.053 μg eq. N9-GP/g at 336 h and
was thereafter below the LLOQ. The concentration in the spinal cord
was 0.159 μg eq. N9-GP/g at 1 h postdose, declining to 0.065 μg eq.
N9-GP/g at 336 h postdose. Approximately half of the investigated tis-
sues contained radioactivity at the ﬁnal time point (12 weeks
postdose); of these, the highest levels (N0.300 μg eq. N9-GP/g) were
present in the pineal body, tooth pulp, adrenal cortex, ex-orbital lachry-
mal gland, and pancreas. The LLOQ in tissues was 0.049 μg eq. N9-GP/g.
The blood to plasma ratio was also assessed and there was no evi-
dence for major partitioning of N9-GP or related radioactivity to red
blood cells suggesting no preferential uptake into red blood cells of
the N9-GP conjugate or any PEG-related entities.
Results from MARG of selected tissues (liver, kidney, spleen, brain,
testis, heart, adrenal, and bone marrow) conducted at three selected
time points (1, 24, and 96 h) complemented the results obtained in
the QWBA study. The study also demonstrated uptake of radioactivity
in hepatocytes and Kupffer cells.3.4. Excretion of [3H]/[14C]N9-GP radioactivity
Radioactivity was excreted in both urine and faeces following a sin-
gle i.v. administration of either [3H]N9-GP or [14C]N9-GP in rats (Table
1). For [3H]N9-GP, the interpolated mean recovery of total radioactivity
was 77%,with ~44%excreted via urine, ~28% recovered in faeces, and 5%
remaining in carcass at 12 weeks postdose. The interpolated mean re-
covery of total radioactivity following a dose of [14C]N9-GP was 112%,
with ~56% excreted via urine, ~49% recovered in faeces, and 7% remain-
ing in carcass. For both tracers, the largest fraction was excreted within
the ﬁrst 24 h postdose half of the total amount recovered was excretedfter a single i.v. administration of [3H]N9-GP 1.5mg/kg (~127 IU/kg, PEG-load ~0.6mg/kg)
phy.
Table 1
Radioactivity (% of dose) recovered from urine and cage wash, faeces, carcass, and overall
following a single i.v. administration of either [3H]N9-GP or [14C]N9-GP in rats.
[3H]N9-GP 1.5
mg/kg
(~0.6 mg/kg PEG)
[14C]N9-GP 0.30 mg/kg (~0.12 mg/kg
PEG)
Urine and cage
wash
44 56
Faeces 28 49
Carcass 5 7
Total 77 112
Table 2
PK parameter estimates from NCA of total plasma radioactivity (by LSC) or N9-GP (by LO-
CI) after single i.v. bolus doses of 0.3 mg/kg [14C]N9-GP or 1.5 mg/kg [3H]N9-GP.
Parameter/dosed compound [14C]N9-GP [3H]N9-GP
Dose (mg/kg) 0.3 1.5
Assay LOCI LSC LOCI LSC
C0 (nM) 91.7 77.2 288 360
AUC(0–1wk) (h*nM) 2350 2940 6650 11,600
AUC (h*nM) 2490 4510 6820 18,600
AUC/dose ([h*nM)/[nmol/kg]) 8300 15,030 4550 12,400
AUCextrap (%) 5.4 0.9 2.5 0.8
CL (mL/h/kg) 1.2 0.68 2.3 0.82
Vss (mL/kg) 65.6 160 92.5 200
t½α (days) NA 2.6 NA 2.7
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in excreta and plasma 12 weeks postdose.t½ (days) 1.7 18 1.4 16
MRT (days) 2.2 9.6 1.7 10
AUC, area under the plasma concentration–time curve; AUCextrap, extrapolated area under
the plasma concentration–time curve from the last sampling point to inﬁnity; CL, total
plasma clearance; Co, back-extrapolated concentration at time zero; LOCI, luminescent ox-
ygen-channelling immunoassay; LSC, liquid scintillation counting; MRT, mean residence
time; NA, not applicable, NCA, non-compartmental analysis; t1/2, terminal elimination
half-life; t1/2α, initial disposition half-life; Vss, volume of distribution. Note: sparse sam-
pling design with each sample representing pooled concentrations from six rats.3.5. PK of N9-GP and [3H]/[14C]N9-GP-related radioactivity in plasma
The composite plasma concentration proﬁles of N9-GP conjugate
and total radioactivity (both tracers) versus time are shown in Fig. 4.
N9-GP conjugate was shown to be relatively rapidly cleared from plas-
ma (terminal t½: 1.4–1.7 days) with a tendency toward a biphasic dis-
position proﬁle. For total plasma radioactivity, a more pronounced
multiphasic disposition proﬁle and a much longer terminal t1/2 (16–
18 days)were observed. For the initial disposition phase of radioactivity
(out to 168 h postdose), a t½α of 2–3 days was estimated. No signiﬁcant
difference was observed between plasma radioactivity proﬁles follow-
ing i.v. dosing with [14C]N9-GP or [3H]N9-GP.
Based on NCA (Table 2), the estimated C0 indicated an initial distri-
bution volume (V0; derived as dose/C0) between 30 and 50 mL/kg for
both N9-GP and total radioactivity. The estimated Vss was 2- to 4-fold
higher for total plasma radioactivity compared with N9-GP, while CL
was 1.5- to 3-fold lower. MRT was approximately 5-fold longer for
total radioactivity versus N9-GP.
No intact N9-GP was detected in plasma 1 week postdose base on
the LOCI assay, whereas 35–38% of the N9-GP-related radioactivity
was estimated to left in circulation at this time. At 12 weeks postdose,
b1% of the dosed radioactivity remained to be eliminated from plasma
based on the estimated AUCextrap (LSC data) (Table 2).
Using an open two-compartment i.v. bolus ﬁrst-order elimination
model parameter estimates of CL, Vc, and Vtot (Table 3) were in the
same range as CL, V0, and Vss estimated from NCA for both N9-GP and
radioactivity data, respectively. CLd was estimated to be 3-fold slower
than CL for total radioactivity, while they were comparable for N9-GP.
CLd was estimated with low precision (high CV%) for N9-GP as a conse-
quence of themore subtle biphasic plasma proﬁle of the conjugate. Still,
for the N9-GP data set produced in this study, a two-compartmentFig. 4.Dose-normalised plasma concentrations of N9-GP (left, LOCI data) and total radioactivity
rats. Purple (squares) and blue (circles) curves are from excretion balance studies and lilac (tria
legend indicates the dose used and radiolabel position (either in the linker or the PEG moiety)model was deemed to ﬁt better than a one-compartment model. Vp
was larger for total radioactivity compared to N9-GP.
Based on the assumption that themain entities circulating in plasma
were either N9-GP or 40 kDa PEG (see radioactivity proﬁling data;
Fig. 5), presumed concentrations of circulating 40 kDa PEG could be de-
rived by subtracting themeasured N9-GP LOCI concentrations from the
total radioactivity concentrations at each sample time point. This gener-
ated a theoretical plasma proﬁle of the 40-kDa PEG after release from
N9-GP.
In order to further test this hypothesis, a simulation was performed
where the two-compartmental model used to describe N9-GP plasma
kinetics (above) was connected to a previously published open two-
compartmental ﬁrst-order eliminationmodel used to describe the plas-
ma kinetics for the same radiolabelled branched 40 kDa PEG
(Bjørnsdottir et al., 2016) (parameter estimates used shown in Table
3). The simulated N9-GP concentrations for Vc was used as input data
for the PEG model, introduced at the same rate as N9-GP was cleared
from plasma. Another assumption was that only 80% of N9-GP was re-
leased as PEG (based on faecal excretion data of radioactivity in this
study [~30%] and in the study where 40 kDa PEG was dosed alone
[~10%]) (Bjørnsdottir et al., 2016). The simulated N9-GP and 40 kDa
PEG plasma proﬁles for the 0.3- and a 1.5-mg/kg i.v. dose of
radiolabelled N9-GP are shown in Fig. 6. Although the simulated plasma
proﬁles of 40 kDa PEG consistently under-predicted the calculated PEG(right, LSC data) versus time after single i.v. dosing of radiolabelled ([3H] or [14C]) N9-GP to
ngle) curve is from a quantitative whole-body autoradiography (QWBA) study. The ﬁgure
.
Table 3
Estimatedmodel parameters afterﬁtting a two-compartmentmodel to plasma concentra-
tions of total radioactivity (measured by LSC) or N9-GP (measured by LOCI) after single i.v.
bolus doses of 0.3 mg/kg [14C]N9-GP or 1.5 mg/kg [3H]N9-GP. Model parameters used to
describe the plasma PK of a 0.6-mg/kg [3H]PEG dose is added for information.
Parameter/assay N9-GP Total radioactivity [3H]PEG (0.6 mg/kg)a
Vc (mL/kg) 51 (9.8) 63 (6.3) 160
Vp (mL/kg) 31 (32) 83 (23) 360
Vtot (mL/kg) 82 (11) 150 (14) 520
CL (mL/h/kg) 1.6 (8.1) 0.69 (8.4) 1.9
CLd (mL/h/kg) 1.5 (82) 0.24 (34) 1.2
CL, total plasma clearance; CLd, intercompartment distribution clearance; LOCI, lumines-
cent oxygen-channelling immunoassay; LSC, liquid scintillation counting; Vc, Vp, and
Vtot, central, peripheral, and total distribution compartments. CV% is stated within
brackets.
a Adapted from Bjørnsdottir et al. (2016).
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the derived data.3.6. Proﬁling of plasma samples following i.v. administration of [3H]N9-GP
and [14C]N9-GP to rats
Selected [3H]N9-GP plasma samples (5 min and up to 4 weeks
postdose) were proﬁled using HPLC with off-line radiochemical detec-
tion. Two peaks were observed in the 5-min sample (Fig. 5). The ﬁrst
peak at 14.25 min co-eluted with 40 kDa PEG reference and the other
at 21.5 min with N9-GP reference. Over time both peaks decreased, de-
tecting only the PEG peak at later time points. Comparable proﬁles were
obtained following analysis of the [14C]N9-GP plasma samples (5 min,
24 h, and 1, 2, 4, and 12 weeks postdose) using HPLC and ofﬂine detec-
tion via AMS (data not shown). These 14C-data further revealed the
presence of the 40-kDa PEG peak at 12 weeks postdose.
Gel electrophoresis of plasma samples collected 5 min, 24 h, and 1
and 3 weeks postdose showed that the N9-GP/PEG ratio changed over
time from containing primarily intact [3H]N9-GP (5 min; ratio: 92:8),
to [3H]PEG (3 weeks; ratio: 20:80); thus, overall, indicating the same
trend as detected via HPLC.Fig. 5.HPLC with radioactivity detection proﬁling of pooled plasma samples (5min, 1 and
4 weeks postdose) following a single i.v. administration of [3H]N9-GP 1.5 mg/kg in rats.3.7. Proﬁling of urine and faeces samples following i.v. administration of
[3H]N9-GP and [14C]N9-GP
Following [3H]N9-GP administration, three urine samples were pro-
ﬁled both by HPLC and gel electrophoresis. HPLC proﬁling of pooled
urine samples showed two peaks in all the proﬁled samples (Fig. 7).
The dominant peak at 14.25min co-elutedwith the 40-kDa [3H]PEG ref-
erence but showed a fronting proﬁle. As smaller-sized PEGs (4–30 kDa)
were tested as reference compounds andwere shown to elute between
the front peak and the 40-kDa PEG. The front peak (4.25min) as well as
the fronting part of themajor peak at 14.25min is expected to represent
smaller-sized PEGs. Itwas not, however, possible to elucidate their exact
structures. The overall proﬁlewas the same in all theproﬁled urine sam-
ples, but the intensity of the peaks decreased over time. These results
are consistent with those from urine samples collected 0–24 h postdose
analysed using gel electrophoresis. Furthermore, comparable proﬁles
were obtained for the [14C]N9-GP urine samples revealing a mixture
of 40 kDa PEG, smaller-sized PEGs, possibly smaller amounts of intact
N9-GP but also other degradation products.
HPLC analysis of pooled faeces samples showed that following
[3H]N9-GP administration a broad fronting peak from about 4 min to
13.5–14.25 min (Fig. 7). This broad peak is expected to be a mixture of
unresolved smaller-sized PEGs (fronting part) and 40 kDa [3H]PEG at
the apex. A minor broad peak eluted at 21.5 min; it cannot be excluded
that this peak contains intact N9-GP. HPLC analysis of the pooled
[14C]N9-GP faeces sample (0–168 h) revealed a similar proﬁle; excre-
tion of 40 kDa PEG, smaller-sized PEGs, possible N9-GP and other degra-
dation products.
4. Discussion
The distribution, metabolism, and elimination of a novel
glycoPEGylated rFIX (N9-GP) were assessed in Wistar rats for
12 weeks following single i.v. doses of 0.3 or 1.5 mg/kg radiolabelled
N9-GP. Rats with normal coagulation were used as this has been the
species of choice in the toxicology programme for N9-GP (Offenberg
et al., 2015b) and also in order to be able to better compare the results
with that observed with other PEGylated compounds. The degradation
pathway for the majority of N9-GP is expected to be the same in
haemophilic and normal animals, as only a minor fraction of the com-
poundwould be activated upon a bleed, and bleedingwould be unlikely
to occur in the controlled environment of a study. Furthermore, metab-
olism studies with haemophilic mice have shown similar results to
those presented here (Bjørnsdottir et al., 2014).
In our studies, N9-GP was radiolabelled with either [3H] in the 40-
kDa PEGmoiety (in the endof each PEG chain) or [14C] in the linkermol-
ecule (glycin) connecting rFIX to PEG. The two different labelling posi-
tions were chosen to allow detection of different parts of the molecule
and evaluation of the fate of the linker and the PEG moiety. The use of
conventional immunoassay (LOCI) enabled kinetic assessment of N9-
GP in plasma.
Given that the [3H]-label was placed at the end of each PEG chain
and that similar placements have been shown to be labile for other
types of compounds, the stability of the [3H]N9-GP tracerwas speciﬁcal-
ly assessed before use. The tracer was shown to be stable throughout
the 12-week experimental period with little or no radiolabelled water
detected in plasma samples. Furthermore, [3H]N9-GP retained close to
full in vitro FIX functional activity (~70%) when compared with a N9-
GP reference compound. The stability of the [14C]N9-GP tracer was not
speciﬁcally tested, but given that the plasma versus time proﬁles
(Fig. 4) and the overall results from the metabolite proﬁling were simi-
lar for the two tracers, theywere both deemed equally useful for the as-
sessment of the biological fate of the PEG moiety incorporated into N9-
GP.
Limitations exist when evaluating and interpreting the total radioac-
tivity data. For example, total radioactivity can be associated with the
Fig. 6. Plasma concentration versus time plots of N9-GP (light blue) and PEGmoiety (dark blue) after i.v. administration of 0.3 (left) or 1.5 (right)mg/kg radiolabelled N9-GP to rats. A two-
compartmental model for N9-GP was connected to a two-compartmental model for 40-kDa PEG and plasma data for N9-GP and 40-kDa PEG was simulated (lines) using parameter
estimates listed in Table 3. For modelling assumptions, see the Discussion. Symbols are observed data for N9-GP (light blue) and derived data (total radioactivity subtracted by N9-GP
concentrations) for PEG alone (dark blue).
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Hence, the PK of radioactivitymay be a composite of more than one en-
tity having potentially very different inherit kinetics. In this study, the
parent compound is in itself a conjugate of two entities with different
kinetics. This issuewasmitigated, at least partially, bymetabolite proﬁl-
ing of plasma and excreta samples, which provided qualitative informa-
tion about the composition of the total radioactivity at different time
points in plasma, urine, and faeces. Another potential limitation relating
to the interpretation of the data was that the LOCI assay was not selec-
tive for the N9-GP conjugate but would also detect any free FIX. It was,
however, deemed likely that these data primarily represented N9-GP.
After an i.v. bolus dose of 0.3 or 1.5mg/kg radiolabelled N9-GP,mea-
surements of intact N9-GP indicated a somewhat biphasic disposition
proﬁle, butwith a limited distribution outside the plasma compartment.
Further, plasma clearance of N9-GP was relatively rapid and the termi-
nal t½ was 1–2 days.Fig. 7. Comparison of HPLC proﬁles of plasma (24 h), urine (0–24 h), and faeces (0–24 h)
following a single i.v. administration of [3H]N9-GP 1.5 mg/kg (~127 IU/kg, PEG-load
~0.6 mg/kg) in rats.By contrast, total radioactivity showed a more pronounced biphasic
plasma proﬁle with an initial disposition phase during the ﬁrst 1–
2 weeks postdose (t½α: 2–3 days) and a long terminal elimination
phase thereafter (t½: 15–18 days). The long terminal t½ was in keeping
with results published for other PEGylated proteins (e.g., Cimzia®, t½ for
40 kDa PEG ~23 days, Nesbitt et al., 2009). Despite the long terminal t½,
the majority of the PEG-related radioactivity of N9-GP was eliminated
within the ﬁrst week. After the early disposition phase it appears that
the elimination of the remaining radioactivity (PEG) from plasma was
a very slow process (Bjørnsdottir et al., 2016), perhaps limited by redis-
tribution back from a peripheral compartment to the central
compartment.
Clearance of the intact conjugate from plasma was ~2-fold faster
than the clearance of total radioactivity (which represents a mixture
of N9-GP and 40 kDa PEG; see below) and the apparent distribution vol-
ume was ~2-fold smaller. The PK of the branched 40 kDa PEG moiety
used in N9-GP has previously been described in the rat at a dose range
of 0.6 to 200 mg/kg [3H]PEG (Bjørnsdottir et al., 2016), with the dispo-
sition kinetics shown to be dose-dependent.
Radioactivity proﬁling of both [3H]- and [14C]N9-GP derived samples
provided similar results; the two main radioactively labelled entities
circulating in plasma were the intact N9-GP conjugate and the 40-kDa
PEG (see Fig. 5 for [3H]N9-GP data). N9-GP was the predominant entity
in plasma at earlier time points (i.e., earlier than 1 week after dosing).
Over time, the amount of 40 kDa PEG initially increased while that of
N9-GP diminished. The 40-kDa PEG moiety was the major peak from
around 1 week after dosing and was still detectable 12 weeks postdose
([14C]-data). Thus, proﬁling data suggested that following degradation
of the N9-GP protein, the intact 40 kDa PEGmoiety circulates in plasma
for a prolonged period. A similar pattern has also been suggested for
other PEGylated compounds (Baumann et al., 2014; Elliott et al.,
2012), including N8-GP (Bjørnsdottir et al., 2016) and Cimzia®
(Nesbitt et al., 2009). Given that the radioactivity proﬁles in plasma
were similar for both radiotracers (Fig. 4), it is thought that the
40-kDa PEG moiety remained attached to the linker molecule.
Distribution data revealed that PEG-related radioactivity was elimi-
nated via the kidneys and liver following an i.v. dose of N9-GP (Fig. 3).
These results correlated with those from excretion studies, in which ra-
dioactivity was detected in both urine and faeces (Table 1). Further-
more, uptake in hepatocytes and Kupffer cells were shown (MARG
data); this is in keeping with biliary excretion to faeces via hepatocytes
and redistribution and/or elimination via the reticuloendothelial system
as previously observed for other PEGylated proteins (Bjørnsdottir et al.,
2016; Webster et al., 2009). Previously published data have suggested
that the protein component of PEGylated proteins is degraded by
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amino acids. The PEGmay then either be cleared along with the protein
or be released back into the blood and/or lymphatics (Baumann et al.,
2014; Bjørnsdottir et al., 2016; Elliott et al., 2012;Webster et al., 2009).
Uptake and distribution via the lymphatic system was evident
(lymph, mandibular lymph node, and spleen) (Fig. 3), indicating that
lymphatic uptake plays a role in the disposition of the N9-GP or PEG
moiety. Considering the size of N9-GP, it is likely that the conjugate
can be distributed into the lymphatic capillaries via passive uptake
after extravasation, in the same manner as other plasma proteins, and
returned back to circulation. Further, a relationship between higher
PEG MW and increased lymphatic redistribution has been described
(Kaminskas et al., 2013; Zou et al., 2013).
Low levels of PEG-related radioactivity were detected in the brain
(1–3% of blood concentrations up to 96 h postdose, where brain levels
were above the LLOQ). This suggested that the PEG-related radioactivity
in the brain was primarily related to the blood with little or no blood–
brain penetration. Similarﬁndings have been published for Peginesatide
(a 40kDa PEGylated erythopoiesis-stimulation agent) (Woodburn et al.,
2012) and for a 20-kDa PEGylated interferon-alfa analogue (Cai et al.,
2012). Consistent with these results, Rudmann et al. (2013) reported
that no PEG was detected in the brain parenchyma of rats receiving re-
peated i.v. doses of unconjugated 40 kDa PEG and following 100 mg/kg
of 40 kDa PEG dosed twiceweekly for 3 months. For N9-GP, as reported
for other marketed drugs such as Cimzia® (Pharmacological
Review(s)—Centre for Drug Evaluation and Research, 2008), and
Peginesatide® (Pharmacological Review(s)—Centre for Drug
Evaluation and Research, 2012), radioactivity was detected in the cho-
roid plexus. As similar levels of radioactivity were detected following
dosing of [3H]N9-GP and 40 kDa [3H]PEG, it appears that there was no
active uptake of N9-GP into the choroid plexus.
Although the recoveries in excreta had to bederived by interpolation
due to the very long study period, it is deemed that the estimated data
are generally representative as the excretion rate was highest in the
ﬁrst period (where consecutive sampling was performed) and then
slower for the rest of the period. Mean interpolated total recovery was
~80% for [3H]N9-GP and ~110% for [14C]N9-GP. The somewhat low
and high recoveries may, however, still be a result of the aforemen-
tioned interpolation as any discrepancies could have an impact on the
ﬁnal estimation. Overall, liver and kidney excretion were of similar
magnitudes and seemingly independent of the radiolabel used and the
two dose levels of N9-GP investigated here.
Based on the large amounts of radioactivity found in faeces (30–
50%) and compared to the much lower fraction excreted when the
PEG moiety was dosed alone (12–13%) (Bjørnsdottir et al., 2016), it is
suggested that receptor-mediated uptake of the protein part of N9-GP
plays a role for hepatic clearance of N9-GP-related radioactivity. Uptake
of the activated part of FIX (FIXa) via low-density lipoprotein receptor-
related protein (Strickland andMedved, 2006) has been described but it
is anticipated that uptake of FIX by other receptors may be involved as
well. The similarity observed between the excretion data and radioac-
tivity plasma proﬁles, independent of the radiolabel position used, sug-
gests that the linker molecule is still attached to the PEG when the
protein part is cleaved during rFIX clearance. Radioactivity proﬁling of
the faeces samples further suggested that a mixture of 40 kDa [3H]PEG
and smaller-sized PEGs were excreted in faeces. A small peak with the
same retention time as N9-GP was, however, also detected in faeces
and excretion of intact N9-GP cannot be completely excluded via this
route.
Extensive urinary excretion of PEGs of all sizes, mainly via renal
elimination, has been previously reported (Woodburn et al., 2012;
Woodburn et al., 2013; Yamaoka et al., 1994). Approximately 40–60%
of the N9-GP-related radioactivitywas recovered in urine in the present
studies, and radioactivity proﬁling data showed a dominant peak in the
chromatogram co-eluting with the 40-kDa PEG reference. A smaller
front peak, as well as the fronting main peak, was thought to be relatedto unresolved smaller-sized PEG fragments. It is unknown if these
smaller fragments stem from catabolism in the kidney after glomerular
ﬁltration before excretion into urine or degradation of the 40-kDa PEG
in the urine after excretion. A peak at the same retention time as intact
N9-GPwas also detected in urine in both studies. It is, however, unlikely
that this peak represent the intact N9-GP conjugate given that the MW
for N9-GP is considerably higher than the reported cut-off for kidney
elimination (~70 kDa) (Caliceti and Veronese, 2003), although this can-
not be fully excluded.
In order to examine whether the plasma radioactivity mainly repre-
sented either radiolabelled N9-GP or 40 kDa radiolabelled PEG, as indi-
cated by the radioactivity proﬁling data, a simplistic simulation
approach was used to explore the relationship between N9-GP and
40 kDa PEG in plasma. Model parameter estimates presented here for
the conjugate and from a previous investigation of the same 40 kDa
PEG (Bjørnsdottir et al., 2016) were used (Table 3). In the simulation,
it was assumed that only 80% of the N9-GP concentrations would
yield free PEG (based on faecal excretion data of the two molecules)
and that the formation rate of free 40 kDa PEG from N9-GP was equal
to the elimination rate of the conjugate from plasma.
Although simulations of the 40-kDaPEGunder-predicted theplasma
levels that would be expected if observed plasma radioactivity only
consisted of N9-GP- and 40 kDa PEG-related radioactivity, the shapes
of the simulated and derived plasma curveswere similar. As the simula-
tion model was very simplistic and it is likely that plasma radioactivity
also consisted of some additional entities, this under-prediction was
not completely unexpected. Furthermore, it should be noted that the as-
sumption that the rate of release of free PEG into plasma (after degrada-
tion of the protein in, for example, liver cells) would equal the removal
rate of N9-GP from plasma is likely an overestimation as this process
may well be delayed. Overall, however, the simulations appeared to
support the notion that the kinetics of the plasma radioactivity were
mainly governed by the kinetics of the two main constituents, N9-GP
(especially at early time points) and 40 kDa PEG (at later time points),
the latter accounting for the long terminal t½ observed.
5. Conclusion
After a single i.v. administration of 0.3 or 1.5mg/kg radiolabelledN9-
GP in male Wistar rats, N9-GP was distributed throughout the body,
with the most abundant levels found in highly vascularised tissues
and lowest levels in the brain and spinal cord. Although the N9-GP con-
jugate was relatively rapidly cleared from plasma (t½: 1–2 days), PEG-
related radioactivity was eliminated in a more pronounced biphasic
manner with a faster initial disposition phase (t½: 2–3 days) and a
slower terminal elimination phase (t½: 15–18 days). Proﬁling of radio-
activity using HPLC indicated that N9-GP and the 40-kDa PEG were
the main constituents in plasma, the former especially at earlier time
points after dosing.
Excretion of PEG-related radioactivity in urine and faeces was quan-
titatively and qualitatively similar, with 40 kDa PEG being the main en-
tity found in both excreta, although smaller-sized PEGswere also found.
The results further suggested that N9-GP is cleared from plasma follow-
ing either receptor-mediated uptake in (e.g., the liver) or via the reticu-
loendothelial system, with subsequent proteolysis of the protein. PEG,
with the linker attached, is thereafter either cleared alongwith the pro-
tein or released back into circulation with a subsequent prolonged
disposition.
Some PEG-related radioactivity, not conﬁned to any particular
organ, was present in the carcass 12 weeks after a single i.v. dose. This
ﬁnding was, however, consistent with the long terminal elimination
t½ of plasma radioactivity.
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